SCYNEXIS (NASDAQ: SCYX) and Corium International (NASDAQ:CORI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings and valuation.
Risk & Volatility
SCYNEXIS has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Corium International has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
This is a breakdown of current ratings for SCYNEXIS and Corium International, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SCYNEXIS presently has a consensus price target of $11.00, suggesting a potential upside of 433.98%. Corium International has a consensus price target of $13.14, suggesting a potential upside of 28.10%. Given SCYNEXIS’s higher possible upside, equities analysts plainly believe SCYNEXIS is more favorable than Corium International.
Institutional & Insider Ownership
36.8% of SCYNEXIS shares are held by institutional investors. Comparatively, 90.1% of Corium International shares are held by institutional investors. 4.0% of SCYNEXIS shares are held by insiders. Comparatively, 45.7% of Corium International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares SCYNEXIS and Corium International’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Corium International||$30.34 million||12.09||-$34.21 million||($1.73)||-5.93|
SCYNEXIS has higher revenue, but lower earnings than Corium International.
This table compares SCYNEXIS and Corium International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Corium International beats SCYNEXIS on 7 of the 12 factors compared between the two stocks.
SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
About Corium International
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.
Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.